CCRT Followed by PD-1 Inhibitor Maintenance Therapy in Locally Advanced ESCC

Abroad (travel likely)RecruitingPHASE3

Conditions

Esophageal Carcinoma · Radiotherapy · Immunotherapy

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

Fudan University Shanghai Cancer Center, Shanghai, China
Contact: Study coordinator (Kuaile Zhao) · kuaile_z@sina.com · +86-21-64175590

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

Clinical Efficacy and Safety of Paclitaxel Polymeric Micelles for Injection in the Treatment of Patients With Taxans-resistant Pancreatic Adenocarcinoma, Cholangiocarcinoma, Lung Cancer, Gastric Cancer, Esophageal Carcinoma, or Breast Cancer

Pancreatic Adenocarcinoma · Cholangiocarcinoma · Lung Cancer

Abroad (travel likely)RecruitingPHASE2

Wuhan, China

Camrelizumab Plus Neoadjuvant Chemotherapy or Chemoradiotherapy Versus Chemoradiotherapy in Resectable ESCC.

Resectable Esophageal Squamous Cell Carcinoma

Abroad (travel likely)RecruitingPHASE3

Shanghai, China · Anyang, China

Immunotherapy in Combination With Chemoradiotherapy in Unresectable Locally Advanced Esophageal Cancer

Esophageal Squamous Cell Carcinoma · Unresectable Locally Advanced Esophageal Cancer

Abroad (travel likely)RecruitingPHASE1, PHASE2

Shanghai, China

Radiotherapy in Patients With Metastatic Esophageal Cancer Responding to PD-1 Inhibitor Plus Chemotherapy

Esophageal Neoplasm Metastatic · Esophageal Cancer Stage IVb

Abroad (travel likely)RecruitingPHASE2

Beijing, China